| Identification | Back Directory | [Name]
GSK321 | [CAS]
1816331-63-1 | [Synonyms]
GSK321
GSK-321
(GSK321
1H-Pyrazolo[4,3-c]pyridine-3-carboxamide, 1-[(4-fluorophenyl)methyl]-4,5,6,7-tetrahydro-N-[3-[(1S)-1-hydroxyethyl]phenyl]-7-methyl-5-(1H-pyrrol-2-ylcarbonyl)-, (7R)- | [Molecular Formula]
C28H28FN5O3 | [MDL Number]
MFCD30533608 | [MOL File]
1816331-63-1.mol | [Molecular Weight]
501.55 |
| Chemical Properties | Back Directory | [Melting point ]
>120°C (dec.) | [Boiling point ]
704.2±60.0 °C(Predicted) | [density ]
1.35±0.1 g/cm3(Predicted) | [storage temp. ]
-20°C Freezer, Under inert atmosphere | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
12.26±0.70(Predicted) | [color ]
White to Pale Yellow |
| Hazard Information | Back Directory | [Uses]
GSK 321 is a potent and selective IDH1 (isocitrate dehydrogenase 1) mutant inhibitor for the treatment of acute myeloid leukemia. | [in vivo]
GSK321 (150 mg/kg; i.p.; daily, for 15 d; male CD-1 mice with IDH1 mutant AML xenograft) reduces leukemic blasts in vivo[1]. | Animal Model: | Male CD-1 mice with IDH1 mutant AML xenograft[1] | | Dosage: | 150 mg/kg | | Administration: | Intraperitoneal injection; daily, for 15 days | | Result: | Decreased in 2HG in IDH1-mutant AML cells. Decreased in the percentage of blast cells (SSClowCD45low/+) and a relative increase in mature lymphoid and granulocytic/monocytic cells. |
| [storage]
4°C, protect from light |
|
|